A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2006
12/06/2006	CN1287858C Foot-and-mouth disease gene engineering polypeptide vaccine and its preparing method
12/06/2006	CN1287857C Method for preparing specific nano vaccine for stomach cancer
12/06/2006	CN1287853C Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway
12/06/2006	CN1287852C Drugs containing as active ingredient midkine or inhibitors thereof
12/06/2006	CN1287850C Vaccines, immunotherapeutics and methods for using same
12/06/2006	CN1287770C Pharmaceutical compositions in particulate form
12/05/2006	US7145055 Backcrossing a C.B-17- SCID mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor gamma chain gene knockout mouse with the backcrossed mouse; estabilishing a stem cell assay; a tumor virus infection models
12/05/2006	US7144998 for preparing antigens or antigen fragments of Clostridum toxins; use in immunogenic and/or vaccine compositions
12/05/2006	US7144991 Use of fusion proteins, especially scFvSA, as diagnostic markers or as cell specific targeting agents.
12/05/2006	US7144985 Diagnosis of diabetes using antibody
12/05/2006	US7144870 Gene therapy; lyases; hyaluronidase; anticancer agents (retinoblastomas); kits
12/05/2006	US7144728 Method of inducing anergic T helper cells
12/05/2006	US7144712 Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
12/05/2006	US7144710 Method for detecting inflammation and inflammatory conditions
12/05/2006	US7144703 Composition
12/05/2006	US7144698 Postweaning multisystemic wasting syndrome virus from pigs
12/05/2006	US7144581 Anticancer agents
12/05/2006	US7144580 M. haemolytica outer membrane protein P1pE as a vaccine or vaccine component against shipping fever
12/05/2006	US7144579 for producing the vectors and suppressing replication/reducing cytotoxicity of vector genome
12/05/2006	US7144578 Mixture of attenuated genetic engineered virus and carrier
12/05/2006	US7144576 Modified pertussis toxin
12/05/2006	US7144575 Methods for selectively stimulating proliferation of T cells
12/05/2006	US7144569 Mutant gliadin protein whose wild-type sequence can be modified by transglutaminase; fusion protein comprising a non-gliadin sequence; kit comprising antibody to interferon- gamma detects recognition by T-cell
12/05/2006	CA2246802C A human cytomegalovirus combined antigen and its use
12/05/2006	CA2179183C Interleukin-1 receptor antagonist decreases severity of acute pancreatitis
12/05/2006	CA2141422C Recombinant equine herpesviruses
11/2006
11/30/2006	WO2009128043A1 Inactivated live-attenuated bluetongue virus vaccine
11/30/2006	WO2006128180A2 Methods for the treatment of disease
11/30/2006	WO2006128103A2 Humanized anti-cd40 antibodies and their methods of use
11/30/2006	WO2006128006A1 Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
11/30/2006	WO2006127798A2 Anti-adhesin based passive immunoprophylactic
11/30/2006	WO2006127571A2 Slotted mandrel for lateral displacement pier and method of use
11/30/2006	WO2006127152A2 Methods for making and using regulatory t cells
11/30/2006	WO2006127020A1 FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PsaA ANTIGEN AND USES THEREOF
11/30/2006	WO2006126835A1 A composition comprising humanized antibody hbbk4 for the treatment of cancer and the use thereof
11/30/2006	WO2006126719A1 Tlr activator and vaccine composition
11/30/2006	WO2006126682A1 Vaccine for prevention/treatment of alzheimer disease
11/30/2006	WO2006126030A2 Malaria vaccines
11/30/2006	WO2006126029A2 Malaria vaccines
11/30/2006	WO2006125983A1 Compositions for inducing an immune response against hepatitis b
11/30/2006	WO2006125921A2 Antibody or antibody fragment coupled with an immunogenic agent
11/30/2006	WO2006125914A2 Use of h11 protein in in vitro diagnosis of streptococcus pyogenes infections
11/30/2006	WO2006125668A2 Anti-cd16 binding molecules
11/30/2006	WO2006125632A2 Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
11/30/2006	WO2006125322A1 Modulation of the integrin-linked kinase signaling pathway provides beneficial human cardiac hypertrophy and post myocardial infarction remodeling
11/30/2006	WO2006112929A3 The hiv gp-41-membrane proximal region arrayed on hepatitis b surface antigen particles as novel antigens
11/30/2006	WO2006109186A3 Early endosome neutralising compouds as vaccine adjuvants
11/30/2006	WO2006099698A3 Novel anti-plgf antibody
11/30/2006	WO2006096488A3 Composition comprising human igg2 antibody and chelating agent
11/30/2006	WO2006094263A3 Compositions and methods for topical application and transdermal delivery of botulinum toxins
11/30/2006	WO2006084226A3 Antibodies that bind to epha2 and methods of use thereof
11/30/2006	WO2006077397A3 Method of producing conjugate vaccines
11/30/2006	WO2006076651A3 Treatment method
11/30/2006	WO2006073940A3 Multi-route administration of immune response modifier compounds
11/30/2006	WO2006024946A3 Improvements relating to meningococcal outer membrane vesicles
11/30/2006	WO2005021707A3 Severe acute respiratory syndrome dna vaccine compositions and methods of use
11/30/2006	WO2005020919A3 Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor
11/30/2006	WO2005009379A3 Polypeptides for inducing a protective immune response against staphylococcus aureus
11/30/2006	WO2004047728A3 Compositions and methods for the treatment of immune related diseases
11/30/2006	US20060270837 Tumor necrosis factor (TNF)-related apoptosis-inducing ligands; anticarcinogenic and antiproliferative agents; graft versus host disease, AIDS, neurodegenerative disorders
11/30/2006	US20060270730 Histone deacetylase inhibitors as immunosuppressants
11/30/2006	US20060270717 Therapeutic combination
11/30/2006	US20060270627 Synthetic oligomannosides, preparation and uses thereof
11/30/2006	US20060270622 Article of manufacture and method for disease treatment
11/30/2006	US20060270600 Anti-cancer agents
11/30/2006	US20060269954 Self-assembling recombinant papillomavirus capsid proteins
11/30/2006	US20060269953 Novel hepatitis B virus
11/30/2006	US20060269917 Compositions, splice variants and methods relating to colon specific gene and proteins
11/30/2006	US20060269912 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
11/30/2006	US20060269593 Pretreatment by applying to skin; transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response
11/30/2006	US20060269577 Allergy inhibition
11/30/2006	US20060269576 Non-injection immunotherapy
11/30/2006	US20060269575 Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
11/30/2006	US20060269574 Method of repairing tendons by surgery
11/30/2006	US20060269573 Methods for treating peritoneal adhesions
11/30/2006	US20060269572 Accelerated vaccination
11/30/2006	US20060269571 Equine West Nile virus immunotherapy
11/30/2006	US20060269570 Recombinant double-stranded RNA phage, and use of the same
11/30/2006	US20060269566 Polypeptide comprising extracellular domain which induces T-cell proliferation response; gene therapy; vaccines; antiproliferative/antitumor agents; cytotoxic T-lymphocyte (CTLA)
11/30/2006	US20060269565 Administering a polypeptide fused to an Fc, has T-cell proliferation inhibiting activity to treat autoimmune encephalomyelitis
11/30/2006	US20060269564 Yersinia spp. polypeptides and methods of use
11/30/2006	US20060269563 NMB1343 from Neisseria meningitidis; provides a mutant toxin having a substitution at one or more of amino Glu-109, Glu-111 or Glu-120; has reduced or eliminated ADP-ribosyltransferase and/or NAD-glycohydrolase activity
11/30/2006	US20060269562 Polypeptides f' of the hepatitis c virus, t epitopeo, and the diagnostic and therapeutic applications thereof
11/30/2006	US20060269561 Compositions and methods for treatment of non-hodgkins lymphoma
11/30/2006	US20060269560 Anti-adhesin based passive immunoprophlactic
11/30/2006	US20060269559 Novel human histone deacetylases
11/30/2006	US20060269558 Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
11/30/2006	US20060269557 Humanized anti-prostate stem cell antigen monoclonal antibody
11/30/2006	US20060269556 Mast cell activation using siglec 6 antibodies
11/30/2006	US20060269555 Tumor necrosis factor (TNF)-related apoptosis-inducing ligands; anticarcinogenic and antiproliferative agents; graft versus host disease, AIDS, neurodegenerative disorders
11/30/2006	US20060269554 DR5 antibodies and uses thereof
11/30/2006	US20060269553 a protein conjugate comprising a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment, with improved in vivo duration and stability; nonimmunogenic
11/30/2006	US20060269552 Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
11/30/2006	US20060269551 Reducing interleukin (IL-20) induced inflammation by administering antibody, fragment or single chain antibody; adult respiratory disease, psoriasis, eczema, dermatitis, septic shock, multiple organ failure, pneumonia, inflammatory bowel disease, arthritis, asthma, ulcerative colitis, Crohn*s disease
11/30/2006	US20060269550 Anti-ghrelin fab antibodies
11/30/2006	US20060269549 Tnf-alpha binding molecules
11/30/2006	US20060269548 Lymphatic endothelial cells materials and methods
11/30/2006	US20060269547 Humanized anti-CD3 specific antibodies
11/30/2006	US20060269546 Androgen-regulated PMEPA1 gene and polypeptides
11/30/2006	US20060269545 Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

1 ... 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 ... 1823